Results 21 to 30 of about 30,982 (215)

Neutralizing Activity of BNT162b2-Elicited Serum

New England Journal of Medicine, 2021
Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages of SARS-CoV-2, first ide...
Yang Liu, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, Pei-Yong Shi   +17 more
openaire   +2 more sources

Strength and durability of antibody responses to BNT162b2 and CoronaVac [PDF]

Vaccine, 2022
ABSTRACT We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine (“Comirnaty”, BioNTech/Fosun Pharma). We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults
Benjamin J. Cowling, Irene O. L. Wong, Eunice Y. C. Shiu, Amber Y. T. Lai, Samuel M. S. Cheng, Sara Chaothai, Kelvin K. H. Kwan, Mario Martín-Sánchez, Leo L. M. Poon, Dennis K. M. Ip, Gabriel M. Leung, Nancy H. L. Leung, J. S. Malik Peiris   +12 more
openaire   +2 more sources

Systems vaccinology of the BNT162b2 mRNA vaccine in humans [PDF]

Nature, 2021
The emergency use authorization of two mRNA vaccines in less than a year from the emergence of SARS-CoV-2 represents a landmark in vaccinology1,2. Yet, how mRNA vaccines stimulate the immune system to elicit protective immune responses is unknown. Here we used a systems vaccinology approach to comprehensively profile the innate and adaptive immune ...
Prabhu S. Arunachalam, Madeleine K. D. Scott, Thomas Hagan, Chunfeng Li, Yupeng Feng, Florian Wimmers, Lilit Grigoryan, Meera Trisal, Venkata Viswanadh Edara, Lilin Lai, Sarah Esther Chang, Allan Feng, Shaurya Dhingra, Mihir Shah, Alexandra S. Lee, Sharon Chinthrajah, Sayantani B. Sindher, Vamsee Mallajosyula, Fei Gao, Natalia Sigal, Sangeeta Kowli, Sheena Gupta, Kathryn Pellegrini, Gregory Tharp, Sofia Maysel-Auslender, Sydney Hamilton, Hadj Aoued, Kevin Hrusovsky, Mark Roskey, Steven E. Bosinger, Holden T. Maecker, Scott D. Boyd, Mark M. Davis, Paul J. Utz, Mehul S. Suthar, Purvesh Khatri, Kari C. Nadeau, Bali Pulendran   +37 more
openaire   +2 more sources

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination [PDF]

Infectious Diseases and Therapy
Introduction Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin levels, a potential marker of myocardial injury, were assessed in healthy participants before and ...
Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups   +25 more
doaj   +2 more sources

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers

Vaccines, 2023
Assessing immune responses post-SARS-CoV-2 vaccination is crucial for optimizing vaccine strategies. This prospective study aims to evaluate immune responses and breakthrough infection in 235 infection-naïve healthcare workers up to 13–15 months after initial vaccination in two vaccine groups (108 BNT/BNT/BNT and 127 ChAd/ChAd/BNT).
Geon Young Ko, Jihyun Lee, Hyunjoo Bae, Ji Hyeong Ryu, Hye-Sun Park, Hyunhye Kang, Jin Jung, Ae-Ran Choi, Raeseok Lee, Dong-Gun Lee, Eun-Jee Oh   +10 more
openaire   +3 more sources

To vaccinate or not to vaccinate – BNT162b2 seroconversion rate and side effects among Polish healthcare workers

International Journal of Occupational Medicine and Environmental Health, 2022
Objectives The study aimed to analyze the effect of BNT162b2 vaccination among Polish healthcare workers in terms of serologic response and adverse events.
Bartosz Siewert, Anna Szabat, Małgorzata Chądzińska-Cebula, Natalia Purpurowicz-Miękus, Piotr Sujkowski, Rafał Spachacz, Grzegorz Dworacki, Jacek Wysocki, Danuta Januszkiewicz-Lewandowska, Ewelina Gowin   +9 more
doaj   +1 more source

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART

Médecine et Maladies Infectieuses Formation, 2022
INTRODUCTION: Le risque de thrombocytopénies thrombotiques immunitaires induites par le vaccin ChAdOx1-nCoV19 a conduit la France à recommander une seconde dose par un vaccin ARNm chez les personnes
Lachâtre, M., Loubet, P., Ninove, L., Gilbert, C., Merrien, D., Carcowski, C., Verdon, R., Maakaroun-Vermesse, Z., Launay, O., Wittkop, L.   +9 more
openaire   +1 more source

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. [PDF]

, 2020
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic.
Nell, Haylene, Hammitt, Laura L, Polack, Fernando P., Dormitzer, Philip R., Moreira, Edson D., Lockhart, Stephen, Koury, Kenneth, Pérez Marc, Gonzalo, Ünal, Serhat, Schaefer, Axel, Absalon, Judith, Roychoudhury, Satrajit, Hammitt, Laura L., Frenck, Robert W., Zerbini, Cristiano, Frenck, Robert W, Bailey, Ruth, Mather, Susan, Swanson, Kena A., Tresnan, Dina B., Thomas, Stephen J, Moreira, Edson D, Jansen, Kathrin U, Gruber, William C, Kalina, Warren V., Li, Ping, Gurtman, Alejandra, Polack, Fernando P, Swanson, Kena A, Jansen, Kathrin U., Perez, John L., Türeci, Özlem, Yozviak, Joseph L, DO, FACP, Perez, John L, Kitchin, Nicholas, Gruber, William C., Kalina, Warren V, Thomas, Stephen J., Tresnan, Dina B, Şahin, Uğur, Cooper, David, Dormitzer, Philip R   +41 more
core   +2 more sources

Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine

The Journal of Infectious Diseases, 2021
Abstract A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Yaki, Saciuk, Jennifer, Kertes, Naama, Shamir Stein, Anat, Ekka Zohar   +3 more
openaire   +3 more sources

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases

Human Vaccines & Immunotherapeutics, 2023
The mRNA-based BNT162b2 and inactivated whole-virus CoronaVac are two widely used COVID-19 vaccines that confer immune protection to healthy individuals. However, hesitancy toward COVID-19 vaccination appeared to be common for patients with neuromuscular
Michael Kwan Leung Yu, Sophelia Hoi Shan Chan, Samuel Cheng, Daniel Leung, Sau Man Chan, Amy Suen Ka Yan, Wilfred Hing Sang Wong, Malik Peiris, Yu Lung Lau, Jaime S Rosa Duque   +9 more
doaj   +1 more source